NASDAQ:LIFE

aTyr Pharma - LIFE Stock Forecast, Price & News

$3.54

-0.11 (-3.01%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.50
▼
$3.73
50-Day Range: $2.63
▼
$3.73
52-Week Range: $2.60
▼
$13.10

Volume: 151,734 shs
Average Volume: 128,176 shs
Market Capitalization: $99.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

aTyr Pharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 515.8% Upside
$21.80 Price Target
Short Interest: Healthy
1.04% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.14
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$43,200 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.75) to ($1.71) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

78th out of 1,117 stocks

Biological Products, Except Diagnostic Industry

11th out of 175 stocks

3.5

Analyst's Opinion

Consensus Rating
aTyr Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.80, aTyr Pharma has a forecasted upside of 515.8% from its current price of $3.54.
Amount of Analyst Coverage
aTyr Pharma has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.04% of the outstanding shares of aTyr Pharma have been sold short.
Short Interest Ratio / Days to Cover
aTyr Pharma has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in aTyr Pharma has recently decreased by 10.39%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
aTyr Pharma does not currently pay a dividend.
Dividend Growth
aTyr Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LIFE.

3.4

News and Social Media Coverage

News Sentiment
aTyr Pharma has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for aTyr Pharma this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for LIFE on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.
MarketBeat Follows
7 people have added aTyr Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, aTyr Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $43,200.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.36% of the stock of aTyr Pharma is held by insiders.
Percentage Held by Institutions
77.96% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for aTyr Pharma are expected to grow in the coming year, from ($1.75) to ($1.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of aTyr Pharma is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of aTyr Pharma is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
aTyr Pharma has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About aTyr Pharma (NASDAQ:LIFE) Stock

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Wall Street Analyst Weigh In

A number of brokerages have commented on LIFE. StockNews.com upgraded aTyr Pharma from a "sell" rating to a "hold" rating in a research report on Thursday, June 9th. HC Wainwright lifted their target price on aTyr Pharma from $11.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, July 21st. Finally, Piper Sandler decreased their price objective on aTyr Pharma from $19.00 to $11.00 and set an "overweight" rating for the company in a research note on Wednesday, May 18th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $21.80.

aTyr Pharma Trading Down 3.0 %

NASDAQ:LIFE traded down $0.11 on Friday, hitting $3.54. 151,734 shares of the company's stock were exchanged, compared to its average volume of 128,176. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10. The stock has a market cap of $99.32 million, a price-to-earnings ratio of -1.96 and a beta of 1.52. The stock has a 50-day moving average of $3.11 and a 200-day moving average of $4.10.

aTyr Pharma (NASDAQ:LIFE - Get Rating) last posted its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.10). During the same quarter last year, the business posted ($0.51) earnings per share. As a group, analysts predict that aTyr Pharma will post -1.75 earnings per share for the current year.

Insider Activity at aTyr Pharma

In related news, CEO Sanjay Shukla acquired 15,000 shares of the firm's stock in a transaction that occurred on Friday, July 1st. The stock was acquired at an average cost of $2.88 per share, for a total transaction of $43,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,798 shares of the company's stock, valued at approximately $117,498.24. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.36% of the stock is currently owned by company insiders.

Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Stock News Headlines

August 11, 2022 | marketwatch.com

aTyr Pharma Gets Fast Track Designation for Efzofitimod

August 11, 2022 | finance.yahoo.com

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

August 13, 2022 | Chaikin Analytics (Ad)

Is Apple Pointing to a Massive Recession in the U.S.?

Apple (AAPL) is making moves behind the scenes to prepare for a downturn…Bloomberg recently reported that the tech giant plans to freeze hiring in some divisions- while remaining cautious on spending through next year. And the thing is, Apple isn’t alone…Bottom-line: Apple might be pointing to a massive recession in the U.S. If you have any serious assets in the market, there is one critical step you must take now.

August 4, 2022 | finance.yahoo.com

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

August 3, 2022 | americanbankingnews.com

Reviewing aTyr Pharma (NASDAQ:LIFE) and Monte Rosa Therapeutics (NASDAQ:GLUE)

July 25, 2022 | americanbankingnews.com

aTyr Pharma (NASDAQ:LIFE) Price Target Increased to $35.00 by Analysts at HC Wainwright

July 24, 2022 | americanbankingnews.com

aTyr Pharma, Inc. (NASDAQ:LIFE) Receives $17.00 Average Price Target from Analysts

June 24, 2022 | finance.yahoo.com

Bullish aTyr Pharma, Inc. (NASDAQ:LIFE) insiders filled their treasuries with US$2.1m worth of stock over last year

August 13, 2022 | Investing Daily (Ad)

27 U.S. Cities Where Stocks Yield 26% a Year

What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

June 14, 2022 | finance.yahoo.com

aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment

June 13, 2022 | finance.yahoo.com

aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference

June 1, 2022 | finance.yahoo.com

aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference

May 23, 2022 | nasdaq.com

Binance Coin Now Buys You the Greatest Amount of aTyr Pharma in the Past Year

May 18, 2022 | seekingalpha.com

aTyr Pharma stock dips after Piper Sandler cuts price target on lung disease drug approval timeline

May 17, 2022 | finance.yahoo.com

aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

May 16, 2022 | finance.yahoo.com

aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis

May 10, 2022 | finance.yahoo.com

Is aTyr Pharma, Inc. (NASDAQ:LIFE) Popular Amongst Institutions?

May 10, 2022 | finance.yahoo.com

aTyr Pharma to Present at Upcoming Investor Conferences in May

May 9, 2022 | investing.com

aTyr Pharma Misses Q1 EPS by 11c

May 9, 2022 | seekingalpha.com

aTyr Pharma, Inc. (LIFE) CEO Dr. Sanjay S. Shukla on Q1 2022 Results - Earnings Call Transcript

May 9, 2022 | finance.yahoo.com

aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update

May 9, 2022 | finance.yahoo.com

Love Hemp Group PLC Announces Update Regarding Trading Suspension

May 8, 2022 | seekingalpha.com

aTyr Pharma Q1 2022 Earnings Preview

May 6, 2022 | benzinga.com

Earnings Outlook For aTyr Pharma

May 2, 2022 | finance.yahoo.com

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results

April 14, 2022 | finance.yahoo.com

aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod

April 13, 2022 | nasdaq.com

ATyr Pharma Adds 7% On Receiving Orphan Drug Status For Its Lead Drug Candidate

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Company Calendar

Last Earnings: 8/09/2021
Today: 8/12/2022
Next Earnings (Confirmed): 8/15/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Life Sciences Tools & Services
Sector: Medical
Current Symbol: NASDAQ:LIFE
CUSIP: 53217V10
CIK: 1339970
Web: www.atyrpharma.com
Phone: (858) 731-8389
Fax: 858-731-8394
Employees: 49
Year Founded: 2005

Price Target and Rating

Average Stock Price Forecast: $21.80
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +380.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,770,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.40%
Return on Assets: -39.44%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.45
Quick Ratio: 16.45

Sales & Book Value

Annual Sales: $10.45 million
Price / Sales: 9.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.93 per share
Price / Book: 0.90

Miscellaneous

Outstanding Shares: 28,056,000
Free Float: 26,833,000
Market Cap: $99.32 million
Optionable: Optionable
Beta: 1.52

Social Links

Key Executives

Dr. Sanjay S. Shukla M.D. (Age 50)
M.S., Pres, CEO & Director
Comp: $816.41k
Ms. Jill M. Broadfoot (Age 60)
Chief Financial Officer
Comp: $561.76k
Ms. Nancy E. Denyes Krueger (Age 54)
Gen. Counsel & Corp. Sec.
Comp: $537.59k
Xiang-Lei Yang Ph.D.
Founder
Ms. Ashlee Dunston
Director of Investor Relations & Corp. Communications
Mr. Peter Villiger
VP of Corp. Devel.
Ms. Danielle Campbell
VP of Human Resource
Dr. Ying J. Buechler Ph.D.
Exec. Director of Biologics Devel. & Manufacturing
Dr. Melissa A. Ashlock (Age 64)
Sr. Advisor
Dr. David J. King (Age 63)
Scientific Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LIFE Stock - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LIFE shares.
View LIFE analyst ratings or view top-rated stocks.
What is aTyr Pharma's stock price forecast for 2022?: 5 Wall Street analysts have issued twelve-month price targets for aTyr Pharma's stock. Their LIFE share price forecasts range from $11.00 to $35.00. On average, they predict the company's share price to reach $21.80 in the next twelve months. This suggests a possible upside of 515.8% from the stock's current price.
View analysts price targets for LIFE or view top-rated stocks among Wall Street analysts.
How have LIFE shares performed in 2022?: aTyr Pharma's stock was trading at $7.47 at the beginning of 2022. Since then, LIFE stock has decreased by 52.6% and is now trading at $3.54.
View the best growth stocks for 2022 here.
When is aTyr Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our LIFE earnings forecast.
How can I listen to aTyr Pharma's earnings call?: aTyr Pharma will be holding an earnings conference call on Monday, August 15th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.
How were aTyr Pharma's earnings last quarter?: aTyr Pharma, Inc. (NASDAQ:LIFE) posted its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.13.
When did aTyr Pharma's stock split?: aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?: 3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).
When did aTyr Pharma IPO?: (LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
What is aTyr Pharma's stock symbol?: aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
Who are aTyr Pharma's major shareholders?: aTyr Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Group One Trading L.P. (0.00%) and D.A. Davidson & CO. (0.04%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends.
How do I buy shares of aTyr Pharma?: Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is aTyr Pharma's stock price today?: One share of LIFE stock can currently be purchased for approximately $3.54.
How much money does aTyr Pharma make?: aTyr Pharma (NASDAQ:LIFE) has a market capitalization of $99.32 million and generates $10.45 million in revenue each year. The biotechnology company earns $-33,770,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.
When was aTyr Pharma founded?: aTyr Pharma was founded in 2005.
How can I contact aTyr Pharma?: aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The official website for the company is www.atyrpharma.com. The biotechnology company can be reached via phone at (858) 731-8389, via email at investorrelations@atyrpharma.com, or via fax at 858-731-8394.

This page (NASDAQ:LIFE) was last updated on 8/13/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

aTyr Pharma - LIFE Stock Forecast, Price & News

aTyr Pharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About aTyr Pharma (NASDAQ:LIFE) Stock

Wall Street Analyst Weigh In

aTyr Pharma Trading Down 3.0 %

Insider Activity at aTyr Pharma

LIFE Stock News Headlines

LIFE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

LIFE Stock - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?

What is aTyr Pharma's stock price forecast for 2022?

How have LIFE shares performed in 2022?

When is aTyr Pharma's next earnings date?

How can I listen to aTyr Pharma's earnings call?

How were aTyr Pharma's earnings last quarter?

When did aTyr Pharma's stock split?

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

What other stocks do shareholders of aTyr Pharma own?

When did aTyr Pharma IPO?

What is aTyr Pharma's stock symbol?

Who are aTyr Pharma's major shareholders?

How do I buy shares of aTyr Pharma?

What is aTyr Pharma's stock price today?

How much money does aTyr Pharma make?

When was aTyr Pharma founded?

How can I contact aTyr Pharma?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™